Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GO-PEG-PTX is a novel drug delivery nanosystem that combines the anticancer drug paclitaxel (PTX) with a graphene oxide (GO) nanosheet carrier that has been modified with polyethylene glycol (PEG). The PEGylation of graphene oxide improves biocompatibility, increases blood circulation time, and enhances tumor targeting[6]. The nanosystem delivers paclitaxel, a microtubule-stabilizing agent, directly to cancer cells, potentially improving therapeutic efficacy and reducing systemic side effects. In vitro and in vivo studies have shown that GO-PEG-PTX exhibits enhanced cytotoxicity to cancer cells (such as A549 and MCF-7) compared to free PTX, with prolonged blood circulation and increased tumor accumulation[5][6]. The system can be further engineered for stimuli-responsive drug release (e.g., pH, thermal, or near-infrared irradiation), allowing for controlled local delivery and possible combinations with photothermal therapy[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paclitaxel-loaded polyethylene glycol-grafted graphene oxide nanosystem.